7. Literaturverzeichnis 1. Abutaily AS, Addis BJ, Roche WR

7. Literaturverzeichnis
1.
Abutaily AS, Addis BJ, Roche WR: Immunohistochemistry in the distinction
between malignant mesothelioma and pulmonary adenocarcinoma: a critical
evaluation of new antibodies. J Clin Pathol. 55 (2002) 662-668
2.
Altmannsberger M: Intermediärfilamentproteine als Marker in der Tumordiagnostik.
Veröff Pathol. (1988) 1271-1305
3.
Altmannsberger M, Osborn M, Droese M, Weber K, Schauer A: Diagnostic value of
intermediate filament antibodies in clinical cytology. Klin Wschr. 62 (1984) 114-123
4.
Amin MB, Tamboli P, Merchant SH, Ordóñez NG, Ro J, Ayala AG, Ro JY:
Micropapillary component in lung adenocarcinoma: a distinctive histologic feature
with possible prognostic significance. Am J Surg Pathol. 26 (2002) 358-364
5.
Attanoos RL, Webb R, Dojcinov SD, Gibbs AR: Malignant epitheloid
mesothelioma: anti-mesothelial marker expression correlates with histological
pattern. Histopathology 39 (2001) 584-588
6.
Baba M, Iyoda A, Yasufuku K, Haga Y, Hoshino H, Sekine Y, Shibuya K, Iizasa T,
Saitoh Y, Hiroshima K, Fujisawa T: Preoperative cytodiagnosis of very small-sized
peripheral-type primary lung cancer. Lung Cancer 37 (2002) 277-280
7.
Blobel GA, Gould VE, Moll R, Lee I, Huszar M, Geiger B, Franke WW:
Coexpression of neuroendocrine markers and epithelial cytoskeletal proteins in
bronchopulmonary neuroendocrine neoplasms. Lab Invest. 52 (1985) 39-51
8.
Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE: The intermediate filament
cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J
Pathol. 121 (1985) 235-247
9.
Blobel GA, Moll R, Franke WW, Vogt-Moykopf I: Cytokeratins in normal lung and
lung carcinomas. I. Adenocarcinomas, squamous cell carcinomas and cultured cell
lines. Virchows Arch Cell Pathol. 45 (1984) 407-429
10.
Bodemann HH, Arnold H, Wannenmacher M, Kraft A: Stadieneinteilung und
Untersuchungsgang beim kleinzelligen Bronchialkarzinom. Dtsch med Wschr. 109
(1984) 910-912
11.
Boenisch T, Farmilo AJ, Stead R, Key M, Welcher R, Harvey R, Atwood KN:
Immunochemical staining methods, Handbook 3rd Edition, DAKO Corporation 2001
12.
Broers JL, de Leij L, Rot MK, ter Haar A, Lane EB, Leigh IM, Waagenar SS,
Vooijs GP, Ramaekers FC: Expression of intermediate filament proteins in fetal
and adult human lung tissues. Differentiation 40 (1989) 119-128
- 72 -
13.
Broers JL, Ramaekers FC, Rot MK, Oostendorp T, Huysmans A, van Muijen GN,
Wagenaar SS, Vooijs GP: Cytokeratins in different types of human lung cancer as
monitored by chain-specific monoclonal antibodies. Cancer Research 48 (1988)
3221-3229
14.
Buccheri G, Ferrigno D: Lung tumor markers of cytokeratin origin: an overview.
Lung Cancer 34 (2001) 65-69
15.
Bucher O, Wartenberg H: Cytologie, Histologie und mikroskopische Anatomie des
Menschen. 12. Aufl. Hans Huber, Bern, Göttingen, Toronto (usw.), 1997, S. 11-20
16.
Bühling KJ, Lepenies J, Witt K: Intensivkurs: Allgemeine und spezielle Pathologie.
2. Aufl. Urban & Fischer, München, Jena, 2000, S. 254
17.
Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F: Expression of p63,
keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum
Pathol. 37 (2006), 542-546
18.
Chausovsky G, Luchansky M, Figer A, Shapira J, Gottfried M, Novis B,
Bogelmann G, Zemer R, Zimlichman S, Klein A: Expression of cytokeratin 20 in
the blood of patients with disseminated carcinoma of the pancreas, colon, stomach
and lung. Cancer 86 (1999) 2398-2405
19.
Chu P, Wu E, Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial
neoplasms: a survey of 435 cases. Mod Pathol. 13 (2000) 962-972
20.
Chyczewski L, Niklinski J, Chyczewska E, Laudanski J, Furman M:
Immunohistochemical analysis of tissue localization of cytokeratin 19 in lung
cancer. Rocz Akad Med Bialymst. 42 (1997) 162-172
21.
Clover J, Oates J, Edwards C: Anti-cytokeratin 5/6: a positive marker for epitheloid
mesothelioma. Histopathology 31 (1997) 140-143
22.
Coulombe PA, Omary MB: “Hard” and “soft” principles defining the structure,
function and regulation of keratin intermediate filaments. Curr Opin Cell Biol. 14
(2002) 110-122
23.
Crapanzano JP, Zakowski MF: Diagnostic dilemmas in pulmonary cytology.
Cancer 93 (2001) 364-375
24.
DAKO Produkt- und Preisliste 2002
25.
Das Laborlexikon der Labormedizin, Internetbeitrag: www.laborlexikon.de
26.
Debus E, Moll R, Franke WW, Weber K, Osborn M: Immunohistochemical
distinction of human carcinomas by cytokeratin typing with monoclonal antibodies.
Am J Pathol. 114 (1984) 121-130
- 73 -
27.
Debus E, Weber K, Osborn M: Monoclonal cytokeratin antibodies that distinguish
simple from stratified squamous epithelia: characterization on human tissue.
EMBO J. 1 (1982) 1641-1647
28.
Fabel H, Konietzko N: Weißbuch Lunge 2005. 3. Aufl. Georg Thieme, Stuttgart,
New York, 2005, S. 45-48
29.
Feddersen CO, v. Wichert P: Diagnostische Strategien beim Bronchialkarzinom.
Internist 35 (1994) 724-729
30.
Ferrigno D, Buccheri G, Biggi A: Serum tumor markers in lung cancer: history,
biology and clinical applications. Eur Respir J. 7 (1994) 186-197
31.
Fischnaller M: Die Bedeutung der Zytologie in der Diagnostik des
Bronchialkarzinoms. Prax Pneumol. 36 (1982) 196-197
32.
Goldstein NS, Thomas M: Mucinous and nonmucinous bronchioloalveolar
adenocarcinomas have distinct staining patterns with thyroid transcription factor
and cytokeratin 20 antibodies. Am J Clin Pathol. 116 (2001) 319-325
33.
Gropp C: Tumormarker, Bedeutung für die klinische Diagnostik. Pneumologie 45
(1991) 137-139
34.
Häußinger K, Huber RM: Bronchialkarzinom (Lungenkrebs). Pneumologie 50
(1996) 599-603
35.
Haraguchi S, Hioki M, Takushima M, Yanagimoto K, Koizumi K, Shimizu K:
Metastatic chest wall tumor suspected to be of lung origin by immunoreactivity for
cytokeratin 7 and 20. Jpn J Thorac Cardiovasc Surg. 54 (2006), 132-136
36.
Hartung W, Schmidt U, Wierch W: Bronchialkarzinom - Pathologische Anatomie
(Untersuchungen an 200 Resektionspräparaten). Prax Pneumol. 36 (1982) 193195
37.
Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM:
Prognostic value of serum tumor markers in patients with lung cancer. Respiration
69 (2002) 25-29
38.
Heckmeyr M: Stellenwert humoraler Tumormarker in der Diagnostik und Therapie
primärer Bronchialkarzinome und intrapulmonaler Metastasen. Pneumologie 53
(1999) 276-282
39.
Heine R: Dritter Kurs, Klinische Zytologie in der Pneumologie Halle/Saale 24.-26.
Juni 2004. Internetbeitrag: www.diakoniewerk-halle.de/KH_Innere1_6.html
40.
Hessel B: Untersuchungen zum Wert der Sputumzytologie bei Lungentumoren.
Internetbeitrag:
www.sundoc.bibliothek.uni-halle.de/diss-online/06/06H123/prom.pdf
- 74 -
41.
Ikeda S, Fujimori M, Shibata S, Okajiama M, Ishizaki Y, Kurihara T, Miyata Y,
Iseki M, Shimizu Y, Tukumoto N, Ozaki S, Asahara T: Combined
immunohistochemistry of beta-catenin, cytokeratin 7 and cytokeratin 20 is useful in
discriminating primary lung adenocarcinomas from metastatic colorectal cancer.
BMC Cancer 6 (2006) 31
42.
Inamura K, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E, Fukayama M,
Ishikawa Y: Pulmonary adenocarcinomas with enteric differentiation: histologic and
immunohistochemical characteristics compared with metastatic colorectal cancers
and usual pulmonary adenocarcinomas. Am J Surg Pathol. 29 (2005) 660-665
43.
Jang KY, Kang MJ, Lee DG, Chung MJ: Utility of thyroid transcription factor-1 and
cytokeratin 7 and 20 immunostaining in the identification of origin in malignant
effusions. Anal Quant Cytol Histol. 23 (2001) 400-404
44.
Jones AM, Hanson IM, Armstrong GR, O´Driscoll BR: Value and accuracy of
cytology in addition to histology in the diagnosis of lung cancer at flexible
bronchoscopy. Respiratory Medicine 95 (2001) 374-387
45.
Junqueira LC, Carneiro J: Histologie. 4. Aufl. Springer, Berlin, Heidelberg, New
York (usw.), 1996, S. 1-29
46.
Kaufmann O, Fietze E, Mengs J, Dietel M: Markers for the differential diagnosis of
poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 116 (2001)
823-830
47.
Kühnel W: Taschenatlas der Zytologie, Histologie und der mikroskopischen
Anatomie. 9. Aufl. Thieme, Stuttgart, New York, 1995, S. 32-39 u. S. 322-335
48.
Kummar S, Fogarasi M, Canova A, Mota A, Ciesielski T: Cytokeratin 7 and 20
staining for the diagnosis of lung and colorectal adenocarcinoma. British Journal of
Cancer 86 (2002) 1884-1887
49.
Lau SK, Desrochers MJ, Luthringer DJ: Expression of thyroid transcription factor-1,
cytokeratin 7 and cytokeratin 20 in bronchioalveolar carcinomas: an
immunohistochemical evaluation of 67 cases. Mod Pathol. 15 (2002) 538-542
50.
Leonhardt P: Atlas der praktischen klinischen Zytodiagnostik bei Erkrankungen im
Thoraxbereich. Johann Ambrosius Barth, Leipzig, 1977, S. 13-14 u. S. 60-63
51.
Lindner J: Lung cancer cytology. Something old, something new. Am J Clin Pathol.
114 (2000) 169-171
52.
Lobeck H: Zytokeratin – Expression in diversen Karzinomen. Vereinfachte
Arbeitshilfe, Fassung 05/2006. Internetbeitrag:
www.klinikum-ernst-von-bergmann-potsdam.de./documents/ZytokeratinTabelle.pdf
- 75 -
53.
Loy TS: Utility of cytokeratin immunostaining in separating pulmonary
adenocarcinomas from colonic adenocarcinomas. Lung Cancer 3 (1995) 278
54.
Macha HN: Bronchialkarzinom. Epidemiologie, Diagnostik, Therapie. Internist 44
(2003) 28-34
55.
Marek W, Krampe S, Dickgreber NJ, Nielsen L, Muti A, Khanavkar B, Müller KM,
Atay Z, Topalidis T, Nakhosteen JA: Automatisierte quantitative Image-Zytometrie
bronchialer Spülflüssigkeiten bei Verdacht auf broncho-pulmonale Tumoren:
Vergleich mit Zytologie, Histologie und klinischer Diagnose. Pneumologie 53
(1999) 583-595
56.
Moll R: Cytokeratine als Differenzierungsmarker. Expressionsprofile von Epithelien
und epithelialen Tumoren. Veröff Pathol. (1993) 1421-197
57.
Moll R, Dhouailly D, Sun TT: Expression of keratin 5 as an distinctive feature of
epithelial and biphasic mesotheliomas. An immunohistochemical study using
monoclonal antibody AE14. Virchows Arch B Cell Pathol Incl Mol Pathol. 58 (1989)
129-145
58.
Moll R, Lowe A, Laufer J, Franke WW: Cytokeratin 20 in human carcinomas. A
new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 140
(1992) 427-447
59.
Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, Barak V: Evaluation of
tissue polypeptide specific antigen, CYFRA 21-1 and carcinoembryonic antigen in
nonsmall cell lung carcinoma. Cancer 82 (1998) 1850-1859
60.
Noll S, Schaub-Kuhnen S: Praxis der Immunhistochemie. Urban & Fischer,
München, Jena, 2000, S. 1-17
61.
Ordóñez NG: Value of Cytokeratin 5/6 immunostaining in distinguishing epithelial
mesothelioma of the pleura from lung adenocarcinomas. Am J Surg Pathol. 22
(1998) 1215-1221
62.
Ordóñez NG: The diagnostic utility of immunohistochemistry in distinguishing
between epitheloid mesotheliomas and squamous carcinomas of the lung: a
comparative study. Mod Pathol. 19 (2006) 417-428
63.
Pujol JL, Grenier J, Parrat E, Lehmann M, Lafontaine T, Quantin X, Michel FB:
Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and
TPS. Am J Respir Crit Care Med. 154 (1996) 725-733
64.
Quinlan RA, Schiller DL, Hatzfeld M, Achtstatter T, Moll R, Jorcano JL, Magin TM,
Franke WW: Patterns of expression and organization of cytokeratin intermediate
filaments. Ann NY Acad Sci. 455 (1985) 282-306
- 76 -
65.
Ritter JH, Boucher LD, Wick MR: Peripheral pulmonary adenocarcinomas with
bronchioloalveolar features: immunophenotypes correlate with histologic pattern.
Mod Pathol. 11 (1998) 566-572
66.
Shah RN, Badve S, Papreddy K, Schindler S, Laskin WB, Yeldandi AV:
Expression of cytokeratin 20 in mucinous bronchioalveolar carcinoma. Hum
Pathol. 33 (2002) 915-920
67.
Siewert JR: Chirurgie. 7. Aufl. Springer, Berlin, Heidelberg, New York (usw.), 2001,
S. 332-358
68.
Sundstrom BE, Stigbrand TI: Cytokeratins and tissue polypeptide antigen. Int J
Biol Markers 9 (1994) 102-108
69.
Su YC, Hsu YC, Chai CY: Role of TTF-1, CK 20 and CK 7 immunohistochemistry
for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J Med
Sci. 22 (2006) 14-19
70.
Suo Z, Holm R, Nesland JM: Squamous cell carcinomas. An immunohistochemical
study of cytokeratins and involucrin in primary and metastatic tumours.
Histopathology 23 (1993) 45-54
71.
Thomas M, Gatzemeier U, Goerg R, Matthiessen W, Morr H, Schoenfeld N,
Ukena D, Stamatis G: Empfehlungen zur Diagnostik des Bronchialkarzinoms.
Pneumologie 2000 (54) 361-371
72.
Tot T, Samii S: The clinical relevance of cytokeratin phenotyping in needle biopsy
of liver metastasis. APMIS 111 (2003) 1075-1082
73.
van de Molengraft FJ, van Niekerk CC, Jap PH, Poels LG: OV-TL 12/30 (keratin 7
antibody) is a marker of glandular differentiation in lung cancer. Histopathology 22
(1993) 35-38
74.
van Dorst EB, van Muijen GN, Litvinov SV, Fleuren GJ: The limited difference
between keratin patterns of squamous cell carcinomas and adenocarcinomas is
explicable by both cell lineage and state of differentiation of tumor cells. J Clin
Pathol. 51 (1998) 679-684
75.
Vyberg M, Moll R: Cytokeratine in der diagnostischen Histopathologie. DAKO
Corporation, 2001, S. 3-15
76.
Welker L: Materialgewinnung für die zytologische Diagnostik und Herstellung der
Präparate. Internetbeitrag: www.diakoniewerk-halle.de/KH_Innere1_6.html
77.
Welker L: Zellbefunde bei sekundären Tumoren der Lunge. Internetbeitrag:
www.diakoniewerk-halle.de/KH_Innere1_6.html
78.
Zusman-Harach SB, Harach HR, Gibbs AR: Cytological features of non-small cell
carcinomas of the lung in fine needle aspirates. J Clin Pathol. 44 (1991) 997-1002
- 77 -